A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-02-07
Adverse events
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 34); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-14 (study day 57); relationship: N
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-05-06 (study day 79); relationship: N
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 90); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-19 (study day 153); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-28 (study day 193); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-01 (study day 197); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-18 (study day 214); relationship: N
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-22 (study day 218); relationship: not assessed; serious criteria: hospitalization
Data queries
No data queries.